J&J Bows Out of Race for Pfizer's $20B Consumer Health Biz Post author:Sam Post published:January 25, 2018 Post category:BioPharma Now insiders say J&J has decided it is no longer interested. Source: BioSpace You Might Also Like AI Takes Off in Biotech, Creating Demand for High Paying Jobs of $500K Plus November 6, 2017 Adaptimmune Announces Closing Of $42 Million Registered Direct Offering April 10, 2017 Ipsen Announces FDA Approval Of Dysport (Abobotulinumtoxina) For The Treatment Of Lower Limb Spasticity In Adults June 15, 2017
Ipsen Announces FDA Approval Of Dysport (Abobotulinumtoxina) For The Treatment Of Lower Limb Spasticity In Adults June 15, 2017
